Reprogramming of Metabolism in Kidney Cancer
- PMID: 32130963
- DOI: 10.1016/j.semnephrol.2019.12.002
Reprogramming of Metabolism in Kidney Cancer
Abstract
Metabolic reprogramming is one of the major steps that tumor cells take during cancer progression. This process allows the cells to survive in a nutrient- and oxygen-deprived environment, to become stress tolerant, and to metastasize to different sites. Recent studies have shown that reprogramming happens in stromal cells and involves the cross-talk of the cancer cell/tumor microenvironment. There are similarities between the metabolic reprogramming that occurs in both noncancerous kidney diseases and renal cell carcinoma (RCC), suggesting that such reprogramming is a means by which renal epithelial cells survive injury and repair the tissue, and that RCC cells hijack this system. This article reviews reprogramming of major metabolism pathways in RCC, highlighting similarities and differences from kidney diseases and potential therapeutic strategies against it.
Keywords: Renal cell carcinoma; energy metabolism; immune evasion; kidney injury; metabolic reprogramming.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Metabolic reprogramming in renal cancer: Events of a metabolic disease.Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188559. doi: 10.1016/j.bbcan.2021.188559. Epub 2021 May 6. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33965513 Free PMC article. Review.
-
Metabolomics and Metabolic Reprogramming in Kidney Cancer.Semin Nephrol. 2018 Mar;38(2):175-182. doi: 10.1016/j.semnephrol.2018.01.006. Semin Nephrol. 2018. PMID: 29602399 Free PMC article. Review.
-
PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8. doi: 10.1152/ajpcell.00322.2014. Epub 2015 Mar 25. Am J Physiol Cell Physiol. 2015. PMID: 25810260 Free PMC article.
-
Metabolic alterations in renal cell carcinoma.Cancer Treat Rev. 2015 Nov;41(9):767-76. doi: 10.1016/j.ctrv.2015.07.002. Epub 2015 Jul 9. Cancer Treat Rev. 2015. PMID: 26169313 Review.
-
Metabolic reprogramming in clear cell renal cell carcinoma.Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Nat Rev Nephrol. 2017. PMID: 28480903 Review.
Cited by
-
Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib.Front Immunol. 2022 Feb 9;13:824607. doi: 10.3389/fimmu.2022.824607. eCollection 2022. Front Immunol. 2022. PMID: 35222406 Free PMC article.
-
Metabolic reprogramming in renal cancer: Events of a metabolic disease.Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188559. doi: 10.1016/j.bbcan.2021.188559. Epub 2021 May 6. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33965513 Free PMC article. Review.
-
Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney.Dis Model Mech. 2020 Nov 27;13(11):dmm045898. doi: 10.1242/dmm.045898. Dis Model Mech. 2020. PMID: 32928875 Free PMC article.
-
A multivariate statistical test for differential expression analysis.Sci Rep. 2022 May 18;12(1):8265. doi: 10.1038/s41598-022-12246-w. Sci Rep. 2022. PMID: 35585166 Free PMC article.
-
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.Int J Mol Sci. 2023 May 7;24(9):8391. doi: 10.3390/ijms24098391. Int J Mol Sci. 2023. PMID: 37176098 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical